scholarly journals Inverse association between baseline renal function and overall survival in patients with metastatic renal cell carcinoma who were treated with molecular-targeted agents

2016 ◽  
Vol 27 ◽  
pp. vi282
Author(s):  
M. Hiroyuki ◽  
H. Miyake ◽  
M. Fujisawa
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Renal Function ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Inverse Association ◽  
Targeted Agents ◽  
Molecular Targeted Agents ◽  
Baseline Renal Function

Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents

2015 ◽  
Vol 11 (3) ◽  
pp. 329-335 ◽  
Author(s):  
Hideaki Miyake ◽  
Mototsugu Muramaki ◽  
Satoshi Imai ◽  
Ken-ichi Harada ◽  
Masato Fujisawa
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Function ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Targeted Agents ◽  
Molecular Targeted Agents

scholarly journals Management of metastatic renal cell carcinoma – mini review

2015 ◽  
Vol 2 (2) ◽  
pp. 75-83 ◽  
Author(s):  
Anubha Bharthuar ◽  
Himanshu Pandey ◽  
Swapan Sood
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Novel Agents ◽  
Targeted Agents ◽  
Clinical Variability ◽  
Biological Heterogeneity ◽  
Molecular Targeted Agents

The management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the last decade. A number of different systemic molecular targeted agents that have been recently approved have improved the survival of patients with mRCC. This mini-review focuses on the implementation of multi-modality therapy in the management of mRCC and the approved indications of the various available novel agents. These novel agents have expanded our armamentarium and improved clinical outcomes of this challenging disease that has considerable biological heterogeneity and clinical variability.  

scholarly journals Metastatic Renal Cell Carcinoma Change Vascularity

2012 ◽  
Vol 2012 ◽  
pp. 1-3
Author(s):  
Takeshi Azuma ◽  
Yukihide Matayoshi ◽  
Yohsuke Sato ◽  
Yujiro Sato ◽  
Yasushi Nagase
Keyword(s):  
Computed Tomography ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Clinical Use ◽  
Targeted Agents ◽  
First Report ◽  
Molecular Targeted Agents

Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a 32-year-old woman with mRCC is presented. These tumors could change vascularity by administration of molecular agents. We could select a drug timely based on findings of computed tomography. To our knowledge, this is the first report that tumor’s character change induced by molecular targeted agents can be detected and the efficacy of molecular targeted agents can be predicted.

Sign in / Sign up

Export Citation Format

Share Document